{"id":32178,"date":"2014-09-26T07:03:19","date_gmt":"2014-09-26T11:03:19","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=32178"},"modified":"2014-09-26T07:03:19","modified_gmt":"2014-09-26T11:03:19","slug":"allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178","title":{"rendered":"Allergan, Inc. (NYSE:AGN) Issues A Statement regarding Correspondence With Valeant Pharmaceuticals Intl Inc(NYSE:VRX)"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 09\/26\/2014 (wallstreetpr) \u2013 According to reports, <strong>Allergan, Inc. (NYSE:AGN)<\/strong> has <a href=\"http:\/\/investing.businessweek.com\/research\/stocks\/news\/article.asp?docKey=600-201409250900BIZWIRE_USPRX____BW5496-1&amp;ex=true&amp;ticker=AGN\" target=\"_blank\">issued<\/a> a statement consisting important information about its recent correspondence with <strong>Valeant Pharmaceuticals Intl Inc (NYSE:VRX)<\/strong>. The statement was published by VRX sometime back.<\/p>\n<p style=\"text-align: justify;\"><strong>Management Call:<\/strong><\/p>\n<p style=\"text-align: justify;\">Board of Directors of\u00a0Allergan, Inc. (NYSE:AGN) is completely aware from the ongoing situation with VRX and its partner Pershing Square Capital Management, LP. It&#8217;s not about who&#8217;s good and who&#8217;s not, but it&#8217;s about who can add value to AGN and its stockholders in the most effective way. AGN has always believed that it&#8217;s capable of achieving more value than VRX offered. All the actions and steps taken by the company in the recent past are evidence that it is fully focused on its goal of achieving 100% efficacy. The firm has increased its efforts especially after\u00a0Valeant Pharmaceuticals Intl Inc (NYSE:VRX) proposed AGN on April 22, 2014. Following are a few things which have played a significant role in Allergan, Inc. (NYSE:AGN)&#8217;s growth over the last some time-<\/p>\n<ul>\n<li style=\"text-align: justify;\">The operational growth of the company is appreciable as it has been growing with double digit rate for the past few years. It has the potential to maintain the same growth rate in the future also.<\/li>\n<li style=\"text-align: justify;\">The growth that AGN experienced in the second quarter of 2014 was phenomenal. No other quarter in last 64 years was as good as the 2Q2014. It&#8217;s the evidence that it&#8217;s able to deliver what it promises its shareholders. If everything goes as per plans, then\u00a0Allergan, Inc. (NYSE:AGN) will break its sales record in the near future.<\/li>\n<li style=\"text-align: justify;\">The company is working on a new strategic plan, which will decrease its annual expenses by $475 million in the near future. It&#8217;s not the first time that company has decided to change its existing strategies, but it&#8217;s a regular process. Whenever it thinks that there is a need of change, it changed without any second thought.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 09\/26\/2014 (wallstreetpr) \u2013 According to reports, Allergan, Inc. (NYSE:AGN) has issued a statement consisting important information about its recent correspondence with Valeant Pharmaceuticals [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":19760,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264,263],"tags":[6035,6036,2046,2045],"stock_ticker":[],"class_list":["post-32178","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","category-technology","tag-allergan-inc-nyseagn","tag-nyseagn","tag-nysevrx","tag-valeant-pharmaceuticals-intl-inc-nysevrx","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Allergan, Inc. (NYSE:AGN) Issues A Statement regarding Correspondence With Valeant Pharmaceuticals Intl Inc(NYSE:VRX) - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Allergan, Inc. (NYSE:AGN) Issues A Statement regarding Correspondence With Valeant Pharmaceuticals Intl Inc(NYSE:VRX) - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 09\/26\/2014 (wallstreetpr) \u2013 According to reports, Allergan, Inc. (NYSE:AGN) has issued a statement consisting important information about its recent correspondence with Valeant Pharmaceuticals [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-09-26T11:03:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/allergan-inc.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"455\" \/>\n\t<meta property=\"og:image:height\" content=\"111\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Alan Masterson\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alan Masterson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178\"},\"author\":{\"name\":\"Alan Masterson\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\"},\"headline\":\"Allergan, Inc. (NYSE:AGN) Issues A Statement regarding Correspondence With Valeant Pharmaceuticals Intl Inc(NYSE:VRX)\",\"datePublished\":\"2014-09-26T11:03:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178\"},\"wordCount\":334,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/allergan-inc.jpg\",\"keywords\":[\"Allergan Inc. (NYSE:AGN)\",\"NYSE:AGN\",\"NYSE:VRX\",\"Valeant Pharmaceuticals Intl Inc (NYSE:VRX)\"],\"articleSection\":[\"Health\",\"Technology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178\",\"name\":\"Allergan, Inc. (NYSE:AGN) Issues A Statement regarding Correspondence With Valeant Pharmaceuticals Intl Inc(NYSE:VRX) - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/allergan-inc.jpg\",\"datePublished\":\"2014-09-26T11:03:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/allergan-inc.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/allergan-inc.jpg\",\"width\":455,\"height\":111},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Allergan, Inc. (NYSE:AGN) Issues A Statement regarding Correspondence With Valeant Pharmaceuticals Intl Inc(NYSE:VRX)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\",\"name\":\"Alan Masterson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"caption\":\"Alan Masterson\"},\"description\":\"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Allergan, Inc. (NYSE:AGN) Issues A Statement regarding Correspondence With Valeant Pharmaceuticals Intl Inc(NYSE:VRX) - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178","og_locale":"en_US","og_type":"article","og_title":"Allergan, Inc. (NYSE:AGN) Issues A Statement regarding Correspondence With Valeant Pharmaceuticals Intl Inc(NYSE:VRX) - Wall Street PR","og_description":"Boston, MA 09\/26\/2014 (wallstreetpr) \u2013 According to reports, Allergan, Inc. (NYSE:AGN) has issued a statement consisting important information about its recent correspondence with Valeant Pharmaceuticals [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-09-26T11:03:19+00:00","og_image":[{"width":455,"height":111,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/allergan-inc.jpg","type":"image\/jpeg"}],"author":"Alan Masterson","twitter_misc":{"Written by":"Alan Masterson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178"},"author":{"name":"Alan Masterson","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90"},"headline":"Allergan, Inc. (NYSE:AGN) Issues A Statement regarding Correspondence With Valeant Pharmaceuticals Intl Inc(NYSE:VRX)","datePublished":"2014-09-26T11:03:19+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178"},"wordCount":334,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/allergan-inc.jpg","keywords":["Allergan Inc. (NYSE:AGN)","NYSE:AGN","NYSE:VRX","Valeant Pharmaceuticals Intl Inc (NYSE:VRX)"],"articleSection":["Health","Technology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178","url":"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178","name":"Allergan, Inc. (NYSE:AGN) Issues A Statement regarding Correspondence With Valeant Pharmaceuticals Intl Inc(NYSE:VRX) - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/allergan-inc.jpg","datePublished":"2014-09-26T11:03:19+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/allergan-inc.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/allergan-inc.jpg","width":455,"height":111},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/allergan-inc-nyseagn-issues-a-statement-regarding-correspondence-with-valeant-pharmaceuticals-intl-incnysevrx-32178#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Allergan, Inc. (NYSE:AGN) Issues A Statement regarding Correspondence With Valeant Pharmaceuticals Intl Inc(NYSE:VRX)"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90","name":"Alan Masterson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","caption":"Alan Masterson"},"description":"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/32178","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=32178"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/32178\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/19760"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=32178"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=32178"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=32178"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=32178"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}